DM
Therapeutic Areas
Anavex Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Blarcamesine (ANAVEX®2-73) | Alzheimer’s Disease | Phase 2b/3 |
| ANAVEX®3-71 | Schizophrenia | Phase 2 |
| ANAVEX®1-41 | CNS Disorders | Preclinical |
| ANAVEX®1066 | Not Specified | Discovery/Preclinical |
Leadership Team at Anavex Life Sciences
CU
Christopher U. Missling, PhD, MS, MBA
President and Chief Executive Officer
JC
Juan Carlos Lopez-Talavera, MD, PhD
Senior Vice President, Head of Research and Development
WL
Wolfgang Liedtke, MD, PhD
Senior Vice President, Global Head of Neurology
TK
Terrie Kellmeyer, PhD
Senior Vice President of Clinical Development
KJ
Kun Jin, PhD
Vice President and Head of Biostatistics
DK
Daniel Klamer, PhD, MS, MBA
Vice President of Business Development and Scientific Strategy
DA
Dr. Adebayo Laniyonu, PhD
Senior Vice President for Nonclinical Development